Antibodies against CSF-1R
US8263079B2 · kind B2 · utility
6Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2011 |
| Grant date | Sep 11, 2012 |
| Priority date | — |
| Expiry date | May 10, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.